News

Raman Malhotra, MD, associate professor of neurology at Washington University in St. Louis, detailed a new position statement from AASM on the vitality of sleep.

The newly updated label language emphasizes the Alzheimer disease stages in which aducanumab was studied, with no additional changes made to its approval pathway.

Reduced cord cross-sectional area and a higher number of cervical cord lesions were the only significant predictors of an EDSS score equal to 6.0.

The clinical fellow at Massachusetts General Hospital discussed whether SUDEP knowledge is at an appropriate level for neurologists and those in other neurology subspecialties.

Analyses suggest treatment of Parkinson disease with amantadine (Gocovri; Adamas) may improve freezing and tremor, as well as other M-EDLs.

The original Narcolepsy Severity Scale was reformulated with the driving-related item removed to assess a pediatric version for the school-aged and adolescent narcolepsy type 1 population.

The acute care nurse practitioner at Overlook Medical Center spoke to the importance of having a multidisciplinary team when treating patients with stroke and the gaps that advanced practice providers can help fill.

Adverse effects of trimethylamine N-oxide were highlighted, as well as the correlation between elevated levels of the byproduct and cardiovascular disease.

The chief medical officer of Scholar Rock provided background on the company’s investigational SMA treatment and its clinical benefit when applied with nusinersen (Spinraza; Biogen).

The acute care nurse practitioner at Overlook Medical Center discussed the presentation she gave at the Atlantic Health Stroke Symposium on the care of the hemorrhagic stroke in the neuro-ICU setting.

The basis for the approval was data from the phase 3 SAkuraSky and SAkuraStar studies, which combined included more than 170 patients who were treated with either satralizumab or placebo.

NeuroMetrix will be evaluating the effectiveness of the transcutaneous electrical nerve stimulation platform in pain relief for patients with neuromyelitis optica spectrum disorder.

Although existing research has shown structural differences between multiple sclerosis and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.

The chief medical officer of Scholar Rock discussed topline results from the phase 2 TOPAZ study of apitegromab in patients with spinal muscular atrophy.

Here's what is coming soon to NeurologyLive.

Maromi Nei, MD, and Michael R. Sperling, MD, shared their insight on the novel inventory tool for predicting sudden unexpected death in epilepsy and their recently published work.

The duo from Cleveland Clinic discussed their presentation from AHS 2021 regarding the effects of COVID-19 on access to telemedicine visits among minorities.

The pediatric headache specialist at NYU Langone discussed adjusting management approaches to pediatric headache and the current state of research within the space.

Neurology News Network for the week ending July 2, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

ICER’s health-benefit price benchmark range for aducanumab is $3000 to $8400 per year for patients with early Alzheimer disease, substantially lower than the current $56,000 annual price listing.

The manuscript was published in the May 2021 issues of BMC Pediatrics.

The differences between the obstructive sleep apnea categories became more apparent when a shorter epoch-to-epoch interval was used to assess this deep learning-based signal.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Scott D. Newsome, DO, and David Li, MD, FRCPC.

The grant will fund a new study to evaluate the effectiveness of brain-responsive neuromodulation in patients with LGS. The study is expected to begin accepting patients in the second half of 2022.

Both high PiB and low entorhinal fluorodeoxyglucose as inclusion criteria reduced 3-fold the number of participants needed in a hypothetical trial compared to using only high PiB.

The pediatric headache specialist at NYU Langone discussed the lifestyle choices children and parents must make to ensure optimal management of pediatric migraine.

Patients who received high-dose blarcamesine experienced a 14.51-point MDS-UPDRS total score improvement compared to placebo in a phase 2 study of the Anavex Life Sciences agent.